利拉鲁肽与2型糖尿病患者的心血管结局 - Suppr

Suppr

超能文献

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

作者信息

Álvarez-Villalobos Neri A, Treviño-Alvarez Andrés M, González-González José G

机构信息

Dr. Jose E. González University Hospital, Monterrey, Mexico

Universidad Autónoma de Nuevo León, Monterrey, Mexico

出版信息

N Engl J Med. 2016 Nov 3;375(18):1797-8. doi: 10.1056/NEJMc1611289.

DOI:10.1056/NEJMc1611289

PMID:28106973

Abstract

摘要

相似文献

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.利拉鲁肽与2型糖尿病患者的心血管结局

N Engl J Med. 2016 Nov 3;375(18):1797-8. doi: 10.1056/NEJMc1611289.

Practice pearl: liraglutide and cardiovascular and renal events in type 2 diabetes.实践要点：利拉鲁肽与2型糖尿病的心血管和肾脏事件

Postgrad Med. 2018 Mar;130(2):154-158. doi: 10.1080/00325481.2018.1430446. Epub 2018 Jan 25.

[Drug therapy of type 2 diabetes and cardiovascular prevention: potentials for liraglutide].[2型糖尿病的药物治疗与心血管预防：利拉鲁肽的潜力]

G Ital Cardiol (Rome). 2009 Jul;10(7):434-47.

Liraglutide and cardiovascular outcomes in type 2 diabetes.利拉鲁肽与2型糖尿病患者的心血管结局

Ann Clin Biochem. 2016 Nov;53(6):712. doi: 10.1177/0004563216663075. Epub 2016 Sep 28.

Liraglutide Improves Glycemic and Blood Pressure Control and Ameliorates Progression of Left Ventricular Hypertrophy in Patients with Type 2 Diabetes Mellitus on Peritoneal Dialysis.利拉鲁肽可改善接受腹膜透析的2型糖尿病患者的血糖和血压控制，并减轻左心室肥厚的进展。

Ther Apher Dial. 2015 Dec;19(6):598-605. doi: 10.1111/1744-9987.12319. Epub 2015 Nov 11.

Cardiovascular safety of liraglutide for the treatment of type 2 diabetes.利拉鲁肽治疗2型糖尿病的心血管安全性。

Expert Opin Drug Saf. 2017 May;16(5):627-635. doi: 10.1080/14740338.2017.1313225. Epub 2017 Apr 26.

Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial.利拉鲁肽对伴有白蛋白尿的 2 型糖尿病患者心血管风险生物标志物的影响：一项随机、安慰剂对照、双盲、交叉试验的亚分析。

Diabetes Obes Metab. 2017 Jun;19(6):901-905. doi: 10.1111/dom.12884. Epub 2017 Mar 2.

Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial.利拉鲁肽疗效和作用的设计：糖尿病心血管结局评估（LEADER）试验。

Am Heart J. 2013 Nov;166(5):823-30.e5. doi: 10.1016/j.ahj.2013.07.012. Epub 2013 Oct 2.

Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis.利拉鲁肽对比西格列汀联合二甲双胍治疗 2 型糖尿病的长期临床和经济结局：CORE Diabetes Model 分析。

J Med Econ. 2012;15 Suppl 2:28-37. doi: 10.3111/13696998.2012.716111. Epub 2012 Aug 13.

Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes - a randomized, single-blinded, cross-over pilot study.胰高血糖素样肽-1类似物利拉鲁肽对2型糖尿病患者冠状动脉微血管功能的影响——一项随机、单盲、交叉先导研究。

Cardiovasc Diabetol. 2015 Apr 22;14:41. doi: 10.1186/s12933-015-0206-3.

引用本文的文献

[Cardiovascular preventive recommendations. PAPPS 2024 thematic updates].[心血管疾病预防建议。PAPPS 2024主题更新]

Aten Primaria. 2024 Nov;56 Suppl 1(Suppl 1):103123. doi: 10.1016/j.aprim.2024.103123.

Evaluating the benefits of the early use of GLP-1 receptor agonists.评估早期使用胰高血糖素样肽-1（GLP-1）受体激动剂的益处。

Lancet. 2025 Jan 18;405(10474):181-183. doi: 10.1016/S0140-6736(24)02255-4. Epub 2024 Nov 12.

Obesity, heart failure with preserved ejection fraction, and the role of glucagon-like peptide-1 receptor agonists.肥胖、射血分数保留的心力衰竭和胰高血糖素样肽-1 受体激动剂的作用。

ESC Heart Fail. 2024 Apr;11(2):649-661. doi: 10.1002/ehf2.14560. Epub 2023 Dec 13.

Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials.胰高血糖素样肽-1（GLP-1）受体激动剂与 2 型糖尿病患者的心血管事件：一项双盲、随机、安慰剂对照临床试验的荟萃分析。

BMC Endocr Disord. 2022 May 12;22(1):125. doi: 10.1186/s12902-022-01036-0.

GLP-1 alleviates NLRP3 inflammasome-dependent inflammation in perivascular adipose tissue by inhibiting the NF-κB signalling pathway.胰高血糖素样肽-1通过抑制核因子κB信号通路减轻血管周围脂肪组织中NLRP3炎性小体依赖性炎症。

J Int Med Res. 2021 Feb;49(2):300060521992981. doi: 10.1177/0300060521992981.

Endothelin receptor antagonists for the treatment of diabetic nephropathy: A meta-analysis and systematic review.内皮素受体拮抗剂治疗糖尿病肾病的荟萃分析与系统评价

World J Diabetes. 2020 Nov 15;11(11):553-566. doi: 10.4239/wjd.v11.i11.553.

The Changing Landscape of Pharmacotherapy for Diabetes Mellitus: A Review of Cardiovascular Outcomes.糖尿病药物治疗的变化格局：心血管结局的综述。

Int J Mol Sci. 2019 Nov 21;20(23):5853. doi: 10.3390/ijms20235853.

Liraglutide improves lipid metabolism by enhancing cholesterol efflux associated with ABCA1 and ERK1/2 pathway.利拉鲁肽通过增强与 ABCA1 和 ERK1/2 通路相关的胆固醇外排来改善脂代谢。

Cardiovasc Diabetol. 2019 Nov 9;18(1):146. doi: 10.1186/s12933-019-0954-6.

Cardiac Autonomic Neuropathy in Obesity, the Metabolic Syndrome and Prediabetes: A Narrative Review.肥胖、代谢综合征和糖尿病前期中的心脏自主神经病变：一篇叙述性综述

Diabetes Ther. 2019 Dec;10(6):1995-2021. doi: 10.1007/s13300-019-00693-0. Epub 2019 Sep 24.

Vascular Inflammation and Oxidative Stress: Major Triggers for Cardiovascular Disease.血管炎症与氧化应激：心血管疾病的主要诱因。

Oxid Med Cell Longev. 2019 Jun 23;2019:7092151. doi: 10.1155/2019/7092151. eCollection 2019.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验